TrialSpark is a technology enabled pharma company. We’ve built an in-house clinical trial engine that runs drug development and clinical trials significantly faster and more efficiently.
We acquire or license assets and then leverage our tech-driven engine to develop these assets in our high priority therapeutic areas, enabling us to take more shots on goal and drive towards value inflection faster.
Download an informational deck about our team and partnership offerings.
Our Partnership Focus
Our approach to partnership is flexible. We are open to conventional asset licensing agreements, joint ventures/co-development, as well as creative strategic arrangements that leverage our partners in genetic sequencing, biomarker discovery, behavioral interventions and more. Our team is flexible in our collaboration approach, rapid in our execution, and has the ability to lead deals, price transactions, and build investment syndicates.
TrialSpark is interested in partnerships to advance development of new and better therapies that improve the standard of care for patients.
Our key partnership criteria:
- Chronic treatments, administered in community based sites of care
- Strong pharmacoeconomic rationale for new therapy
- Identifiable patient populations
- High unmet patient need
Licensing & Business Development Team
Head of Investments
Jorge Ramirez is the Head of Investments & VP Business Development at TrialSpark. Previously, Jorge was with H.I.G. Capital where he was responsible for development stage and growth investments in the biotechnology, medical device and diagnostics industries. During his six years with H.I.G., Jorge represented the firm in several successful investments. Prior to H.I.G., Jorge was with ProQuest Investments, a healthcare dedicated venture capital firm, and Monitor Company, a strategy consulting firm. He currently serves on the advisory board of the NJ Bioscience Center, a life sciences incubator funded by the NJ Economic Development Authority. Jorge earned degrees in neuroscience and Spanish literature from Amherst College and an M.B.A. from Harvard Business School.
Director, Business Development
Lamia Mamoon is a Director of Business Development & Investments at TrialSpark. Before joining TrialSpark, she was the Head of Business Operations at Floragraph, an early stage microbiome genomic analysis startup. Previously, Lamia was the Head of Business Development at OpenBiome, a microbiome CRO and public stool bank. She also has corporate development experience in the healthcare, education and energy spaces with significant international experience. Lamia holds an MBA from MIT Sloan and is currently pursuing a masters in Biology and Genomics from Tufts University. She earned a BS in Business Administration and Energy and Resources from the University of California, Berkeley.
Senior Manager, Business Development
Emma Nealon is a Senior Manager of Business Development & Investments at TrialSpark. Prior to joining TrialSpark, she was an equity research analyst covering small and mid-cap biotechnology at Cantor Fitzgerald. Previously, Emma also held associate positions in equity research in the biotechnology sector at both Cantor and Oppenheimer, and started her career at ICR working in capital markets advisory and investor relations for both public and private biopharma companies. Emma graduated from Georgetown University with a BS in Biology.
Manager, Business Development
Ruben Atilho is a Manager of Business Development & Investments at TrialSpark. Previously, he was a consultant at McKinsey & Company where he served top pharma, CDMOs, and nonprofits on topics related to strategy, merger management, procurement and due diligence. Ruben earned his PhD in Molecular Biophysics and Biochemistry from Yale University as a National Science Foundation Fellow and received his B.S. in Biochemistry from Quinnipiac University.
Manager, Business Development
Edward Marks, PhD
Edward Marks is a Business Development Manager at TrialSpark. Previously, he worked in sell side equity research at Ladenburg Thalmann and H.C. Wainwright covering rare pediatric neurology, neuropsych, and specialty pharmaceuticals. Prior to his equity research roles, Edward worked at Deallus Consulting advising large-cap pharmaceutical clients on competitive strategy and product-market fit with a focus in neurology and immune-oncology. Edward earned his B.S. in Microbial Biotechnology from Rutgers University, and his P.S.M. in Biotechnology and Ph.D. in Molecular Medicine from the University of Delaware.
Manager, Business Development
Chris Walters is a Manager of Business Development & Investments at TrialSpark. Prior to joining TrialSpark, Chris worked as a life science strategy consultant at Blue Matter Consulting, focusing on therapeutic/diagnostic product launch and corporate strategy. Previously, Chris worked as a business development professional at the University of Pennsylvania’s technology transfer office (PCI), where he managed a portion of Penn’s patent portfolio and secured licensing agreements for university inventions. Chris has a PhD in Chemistry from the University of Pennsylvania and a BS in Biochemistry from the University of Michigan.
Senior Associate, Business Development
Jack Rosenberg is a Senior Associate of Business Development & Investments at TrialSpark where he focuses on asset acquisitions and drug development partnerships. Jack has held multiple roles at TrialSpark, supporting the company’s growth initiatives and mission to bring new treatments to patients faster and more efficiently. Previously, he worked in investment banking for Canaccord Genuity advising tech-enabled healthcare services and digital media companies on M&A transactions. Jack earned his undergraduate degree in Science, Technology, and International Affairs from Georgetown University.
CEO & Co-Founder
Ben Liu is the co-founder and CEO of TrialSpark. He received his DPhil at Oxford as a Rhodes Scholar, leveraging machine-learning, AI, and big-data to develop diagnostics and therapeutics for Parkinson’s and Alzheimer’s disease. During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start TrialSpark. Before TrialSpark, Ben graduated from Yale where he was awarded the college’s highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Mellon Fellow.
Chief Medical Officer
Gavin Corcoran, MD
Gavin Corcoran is the Chief Medical Officer at TrialSpark. He oversees the scientific and medical input to the drug development process from the business development efforts to identify new products through the medical oversight of clinical trials to the regulatory filings and approval of the products. Prior to joining TrialSpark, he held several senior leadership roles including the CMO at Allergan and Stiefel where he provided oversight of the regulatory approval of many products across a number of therapeutic areas. His academic training is in infection diseases and he was on the faculty of the University of Texas Health Sciences Center in San Antonio, TX prior to joining the pharmaceutical industry over 20 years ago.
Former Chief R&D Officer, Allergan
Former President EMD Serono Inc.
Former CEO Sandoz
Former EVP Sanofi, CBO Teva
Jeff Wilkins, MD
Former CMO Lycera, Zyla
Former COO Reneo, AmpliPhi
Ken Somberg, MD
Former CMO Covance
Former VP of Engineering, Facebook
Lawrence Olanoff, MD, PhD
Former COO & President, Forest (Allergan)
Sr. VP Reg Affairs, Forest
Our Therapeutic Areas
TrialSpark is seeking partnership opportunities to develop mechanisms with therapeutic potential in this space. Improving diagnostics and engaged patient advocacy groups present an opportunity to accelerate development of therapies to improve standard of care over expensive biologics.
CNS (Neurology & Psychiatry)
TrialSpark is interested in promising novel mechanisms to address CNS diseases. Where current first-line therapies have poor response rates, we believes that biomarker guided therapies have the potential to deliver substantial improvement over standard of care to distinct patient populations.
Dermatology is an area where TrialSpark has significant experience in reducing trial timelines through novel recruitment mechanisms and augmenting site performance. TrialSpark is keen on expanding our presence in this space through acquiring best in class assets with novel MOAs.
Given the underlying pathologies common to many Cardiovascular and Metabolic diseases, TrialSpark is interested in partnering to advance development of mechanisms with various potential applications as well as combination therapies that address the role of diet and lifestyle in disease progression.